AnaptysBio, Inc.
ANABNASDAQHealthcare● Active
$51.36
+$0.99(+1.97%)
Market Cap$2.2B
P/E Ratio—
52W High$72.36
52W Low$11.404
AnaptysBio, Inc. (ANAB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ANAB · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.23B | $0.09B | $0.02B | $0.01B | $0.06B |
| Cost of Revenue | $0.00B | $0.16B | $0.13B | $0.09B | $0.10B |
| Gross Profit | $0.23B | ($0.07B) | ($0.12B) | ($0.08B) | ($0.04B) |
| Gross Margin %(computed) | 98.97% | -79.49% | -671.01% | -763.21% | -55.91% |
| Operating Expenses | |||||
| R&D Expenses | $0.14B | $0.16B | $0.14B | $0.09B | $0.10B |
| G&A Expenses | $0.05B | $0.04B | $0.04B | $0.04B | $0.02B |
| Total Operating Expenses | $0.18B | $0.04B | $0.05B | $0.04B | $0.02B |
| Operating Income | $0.05B | ($0.11B) | ($0.16B) | ($0.12B) | ($0.06B) |
| Operating Margin %(computed) | 20.42% | -125.93% | -958.27% | — | -89.93% |
| Interest Income | $0.01B | $0.02B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.08B | $0.05B | $0.02B | $0.02B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.15B) | ($0.16B) | ($0.13B) | ($0.06B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.15B) | ($0.16B) | ($0.13B) | ($0.06B) |
| Net Margin %(computed) | -5.64% | -159.10% | -953.66% | — | -91.49% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B |
| EBITDA | $0.05B | ($0.09B) | ($0.16B) | ($0.11B) | ($0.06B) |
| EBITDA Margin %(computed) | 21.45% | -101.60% | -911.70% | — | -88.18% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more AnaptysBio, Inc. data
About AnaptysBio, Inc. (ANAB) Income Statement
AnaptysBio, Inc. (ANAB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ANAB reported revenue of $0.23B, gross profit of $0.23B (gross margin 98.97%), and net income of ($0.01B) — a net profit margin of -5.64%.
Frequently asked questions
ANAB · 4 questionsAnaptysBio, Inc. (ANAB) reported revenue of $0.23B for 2025, up 157.0% year-over-year.
ANAB revenueANAB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08